17 research outputs found

    List of titles reviewed

    No full text
    This dataset contains the 2214 titles reviewed (393 duplicates are not included here). Codebook: OUTCOME_title = FINAL outcome of Title review: 2.00 EXCLUDED (do not review abstract), 3.00 INCLUDED (review ABSTRACT), 5.00 NO ABSTRACT, 9.00 extra reference (manual review of retrieved articles). OUTCOME_abstract = FINAL outcome of Abstract review: 2.00 EXCLUDED (do not review abstract), 3.00 NCLUDED (review ABSTRACT), 5.00 NO ABSTRACT, 9.00 extra reference (manual review of retrieved articles). OUTCOME_paper = FINAL outcome paper: 1.00 INCLUDED in the systematic review, 2.00 EXCLUDED from Systematic review, 4.00 INCLUDED in syst. rev. (EXTRA ref), 8.00 n/a. Title = Title of the manuscript. Authors = List of authors

    Comorbidity and cervical cancer survival of Indigenous and non-Indigenous Australian women: A semi-national registry-based cohort study (2003-2012)

    No full text
    <div><p>Background</p><p>Little is known about the impact of comorbidity on cervical cancer survival in Australian women, including whether Indigenous women’s higher prevalence of comorbidity contributes to their lower survival compared to non-Indigenous women.</p><p>Methods</p><p>Data for cervical cancers diagnosed in 2003–2012 were extracted from six Australian state-based cancer registries and linked to hospital inpatient records to identify comorbidity diagnoses. Five-year cause-specific and all-cause survival probabilities were estimated using the Kaplan-Meier method. Flexible parametric models were used to estimate excess cause-specific mortality by Charlson comorbidity index score (0,1,2+), for Indigenous women compared to non-Indigenous women.</p><p>Results</p><p>Of 4,467 women, Indigenous women (4.4%) compared to non-Indigenous women had more comorbidity at diagnosis (score ≥1: 24.2% vs. 10.0%) and lower five-year cause-specific survival (60.2% vs. 76.6%). Comorbidity was associated with increased cervical cancer mortality for non-Indigenous women, but there was no evidence of such a relationship for Indigenous women. There was an 18% reduction in the Indigenous: non-Indigenous hazard ratio (excess mortality) when comorbidity was included in the model, yet this reduction was not statistically significant. The excess mortality for Indigenous women was only evident among those without comorbidity (Indigenous: non-Indigenous HR 2.5, 95%CI 1.9–3.4), indicating that factors other than those measured in this study are contributing to the differential. In a subgroup of New South Wales women, comorbidity was associated with advanced-stage cancer, which in turn was associated with elevated cervical cancer mortality.</p><p>Conclusions</p><p>Survival was lowest for women with comorbidity. However, there wasn’t a clear comorbidity-survival gradient for Indigenous women. Further investigation of potential drivers of the cervical cancer survival differentials is warranted.</p><p>Impact</p><p>The results highlight the need for cancer care guidelines and multidisciplinary care that can meet the needs of complex patients. Also, primary and acute care services may need to pay more attention to Indigenous Australian women who may not obviously need it (i.e. those without comorbidity).</p></div
    corecore